Current molecular diagnostics of breast cancer and the potential incorporation of microRNA

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, de la Garza Salazar J, Pritchard K et al. The global breast cancer burden: variations in epidemiology and survival. Clin. Breast Cancer6(5), 391–401 (2005).
   PubMedGoogle Scholar
• Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J.12(Suppl. 1), S70–S80 (2006).
   PubMed Web of Science ®Google Scholar
• Breast Cancer Screening. IARC Press, Lyon, France (2002).
   Google Scholar
• Groot MT, Baltussen R, Uyl-de Groot CA, Anderson BO, Hortobagyi GN. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J.12(Suppl. 1), S81–S90 (2006).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol.608, 1–22 (2007).
   PubMed Web of Science ®Google Scholar
• Moore S. Managing treatment side effects in advanced breast cancer. Semin. Oncol. Nurs.23(4 Suppl. 2), S23–S30 (2007).
   Google Scholar
• Buchholz TA. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N. Engl. J. Med.360(1), 63–70 (2009).
   PubMed Web of Science ®Google Scholar
• NIH consensus conference. Treatment of early-stage breast cancer. JAMA265(3), 391–395 (1991).
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl Cancer Inst. Monogr.30, 5–15 (2001).
   Google Scholar
• Eifel P, Axelson JA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl Cancer Inst.93(13), 979–989 (2001).
   PubMed Web of Science ®Google Scholar
• Consensus conference 2000: adjuvant therapy for breast cancer. National Institutes of Health Consensus Development Conference Statement November 1–3, 2000. Cancer Control8(1), 55 (2001).
   PubMedGoogle Scholar
• Buzdar A. The place of chemotherapy in the treatment of early breast cancer. Br. J. Cancer78(Suppl. 4), 16–20 (1998).
   PubMedGoogle Scholar
• Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J. Clin. Oncol.26(7), 1059–1065 (2008).
   PubMed Web of Science ®Google Scholar
• Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer103(11), 2241–2251 (2005).
   PubMed Web of Science ®Google Scholar
• McGuire WL, De La Garza M, Chamness GC. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res.37(3), 637–639 (1977).
   PubMed Web of Science ®Google Scholar
• Hull DF 3rd, Clark GM, Osborne CK, Chamness GC, Knight WA 3rd, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res.43(1), 413–416 (1983).
   PubMed Web of Science ®Google Scholar
• Greene GL, Sobel NB, King WJ, Jensen EV. Immunochemical studies of estrogen receptors. J. Steroid Biochem.20(1), 51–56 (1984).
   PubMedGoogle Scholar
• Jensen EV, Greene GL, DeSombre ER. Immunochemical studies of estrogen receptors. Prog. Clin. Biol. Res.249, 283–305 (1987).
   PubMedGoogle Scholar
• Taylor CR, Shi SR, Chaiwun B, Young L, Imam SA, Cote RJ. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum. Pathol.25(3), 263–270 (1994).
   PubMed Web of Science ®Google Scholar
• Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods. Breast J.6(3), 189–196 (2000).
   PubMedGoogle Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science229(4717), 974–976 (1985).
   PubMed Web of Science ®Google Scholar
• Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol.8(1), 103–112 (1990).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, Mooi WJ, Wisman P, Peterse JL, Nusse R. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene2(2), 175–178 (1980).
   Google Scholar
• Slamon DJ. Proto-oncogenes and human cancers. N. Engl. J. Med.317(15), 955–957 (1987).
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med.131(1), 18 (2007).
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.25(33), 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar
• Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell5(6), 607–616 (2004).
   PubMed Web of Science ®Google Scholar
• Jansen MP, Sieuwerts AM, Look MP et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J. Clin. Oncol.25(6), 662–668 (2007).
   PubMed Web of Science ®Google Scholar
• Ma XJ, Salunga R, Dahiya S et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res.14(9), 2601–2608 (2008).
   PubMed Web of Science ®Google Scholar
• van ‘t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871), 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Buyse M, Loi S, van ‘t Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst.98(17), 1183–1192 (2006).
   PubMed Web of Science ®Google Scholar
• Glas AM, Floore A, Delahaye LJ et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics7, 278 (2006).
   PubMed Web of Science ®Google Scholar
• Cronin M, Sangli C, Liu ML et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem.53(6), 1084–1091 (2007).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol.24(23), 3726–3734 (2006).
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell75(5), 843–854 (1993).
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science294(5543), 853–858 (2001).
   PubMed Web of Science ®Google Scholar
• Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science294(5543), 858–862 (2001).
   PubMed Web of Science ®Google Scholar
• Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science294(5543), 862–864 (2001).
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res.36, D154–D158 (2008).
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res.34, D140–D144 (2006).
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res.32, D109–D111 (2004).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116(2), 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev.17(24), 3011–3016 (2003).
   PubMed Web of Science ®Google Scholar
• Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature409(6818), 363–366 (2001).
   PubMed Web of Science ®Google Scholar
• Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science293(5531), 834–838 (2001).
   PubMed Web of Science ®Google Scholar
• Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell123(4), 631–640 (2005).
   PubMed Web of Science ®Google Scholar
• Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol.3(3), e85 (2005).
   PubMed Web of Science ®Google Scholar
• Bernstein E, Kim SY, Carmell MA et al. Dicer is essential for mouse development. Nat. Genet.35(3), 215–217 (2003).
   PubMed Web of Science ®Google Scholar
• Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science303(5654), 83–86 (2004).
   PubMed Web of Science ®Google Scholar
• Miska EA. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev.15(5), 563–568 (2005).
   PubMed Web of Science ®Google Scholar
• Miska EA, Alvarez-Saavedra E, Townsend M et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol.5(9), R68 (2004).
   PubMed Web of Science ®Google Scholar
• Blenkiron C, Goldstein LD, Thorne NP et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol.8(10), R214 (2007).
   PubMed Web of Science ®Google Scholar
• Verghese ET, Hanby AM, Speirs V, Hughes TA. Small is beautiful: microRNAs and breast cancer-where are we now? J. Pathol.215(3), 214–221 (2008).
   PubMed Web of Science ®Google Scholar
• Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch.452(1), 1–10 (2008).
   PubMed Web of Science ®Google Scholar
• Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell113(1), 25–36 (2003).
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA101(9), 2999–3004 (2004).
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer6(11), 857–866 (2006).
   PubMed Web of Science ®Google Scholar
• Gaur A, Jewell DA, Liang Y et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res.67(6), 2456–2468 (2007).
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature435(7043), 834–838 (2005).
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA99(24), 15524–15529 (2002).
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT et al. A microRNA polycistron as a potential human oncogene. Nature435(7043), 828–833 (2005).
   PubMed Web of Science ®Google Scholar
• Ota A, Tagawa H, Karnan S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31–q32 amplification in malignant lymphoma. Cancer Res.64(9), 3087–3095 (2004).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res.65(16), 7065–7070 (2005).
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA14(11), 2348–2360 (2008).
   PubMed Web of Science ®Google Scholar
• Lu Z, Liu M, Stribinskis V et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene27(31), 4373–4379 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res.18(3), 350–359 (2008).
   PubMed Web of Science ®Google Scholar
• Sempere LF, Christensen M, Silahtaroglu A et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res.67(24), 11612–11620 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem.282(19), 14328–14336 (2007).
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene26(19), 2799–2803 (2007).
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA103(7), 2257–2261 (2006).
   PubMed Web of Science ®Google Scholar
• Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem.283(2), 1026–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Huang GL, Zhang XH, Guo GL et al. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol. Rep.21(3), 673–679 (2009).
   PubMed Web of Science ®Google Scholar
• Qian B, Katsaros D, Lu L et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res. Treat. (2008) (Epub ahead of print).
   Google Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature449(7163), 682–688 (2007).
   PubMed Web of Science ®Google Scholar
• Gee HE, Camps C, Buffa FM et al. MicroRNA-10b and breast cancer metastasis. Nature455(7216), E8–E9 (2008).
   Web of Science ®Google Scholar
• Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 Expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res.68(13), 5004–5008 (2008).
   PubMed Web of Science ®Google Scholar
• Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol.21(5), 1132–1147 (2007).
   PubMed Web of Science ®Google Scholar
• Tavazoie SF, Alarcon C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature451(7175), 147–152 (2008).
   PubMed Web of Science ®Google Scholar
• Mattie MD, Benz CC, Bowers J et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer5, 24 (2006).
   PubMed Web of Science ®Google Scholar
• Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem.282(2), 1479–1486 (2007).
   PubMed Web of Science ®Google Scholar
• Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res.66(3), 1277–1281 (2006).
   PubMed Web of Science ®Google Scholar
• Abdelrahim M, Samudio I, Smith R 3rd, Burghardt R, Safe S. Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J. Biol. Chem.277(32), 28815–28822 (2002).
   PubMed Web of Science ®Google Scholar
• Murray GI, Taylor MC, McFadyen MC et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res.57(14), 3026–3031 (1997).
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res.66(18), 9090–9098 (2006).
   PubMed Web of Science ®Google Scholar
• Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity. J. Biol.7(2), 6 (2008).
   PubMedGoogle Scholar
• Camps C, Buffa FM, Colella S et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res.14(5), 1340–1348 (2008).
   PubMed Web of Science ®Google Scholar
• Foekens JA, Sieuwerts AM, Smid M et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc. Natl Acad. Sci. USA105(35), 13021–13026 (2008).
   PubMed Web of Science ®Google Scholar
• Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat. Rev. (2009).
   PubMedGoogle Scholar
• Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin. Cancer Res.14(2), 360–365 (2008).
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Filkowski J, Meservy J et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther.7(7), 2152–2159 (2008).
   PubMed Web of Science ®Google Scholar
• Miller TE, Ghoshal K, Ramaswamy B et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem.283(44), 29897–29903 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Yang H et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem.283(45), 31079–31086 (2008).
   PubMed Web of Science ®Google Scholar
• Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol. Biol.9, 76 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, Feilotter H. An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J. Mol. Diagn.10(6), 513–519 (2008).
   PubMed Web of Science ®Google Scholar
• Li J, Smyth P, Flavin R et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol.7, 36 (2007).
   PubMed Web of Science ®Google Scholar
• Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J. Clin. Pathol.62(1), 84–88 (2009).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.351(8), 781–791 (2004).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol.23(7), 1420–1430 (2005).
   PubMed Web of Science ®Google Scholar
• Ralph DA, Zhao LP, Aston CE et al. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer109(10), 1940–1948 (2007).
   PubMed Web of Science ®Google Scholar
• Viale G, Maiorano E, Pruneri G et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann. Surg.241(2), 319–325 (2005).
   PubMed Web of Science ®Google Scholar
• Suijkerbuijk KP, van der Wall E, Vooijs M, van Diest PJ. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology75(2), 149–152 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma P, Sahni NS, Tibshirani R et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res.7(5), R634–44 (2005).
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell131(6), 1109–1123 (2007).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Casalini P, Piovan C et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res.69(6), 2195–2200 (2009).
   PubMed Web of Science ®Google Scholar
• Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res.19(4), 439–448 (2009).
   PubMed Web of Science ®Google Scholar
• Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. (2009).
   PubMedGoogle Scholar
• Huang Q, Gumireddy K, Schrier M et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol.10(2), 202–210 (2008).
   PubMed Web of Science ®Google Scholar
• Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res.67(22), 11001–11011 (2007).
   PubMed Web of Science ®Google Scholar
• Yu Z, Wang C, Wang M et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J. Cell Biol.182(3), 509–517 (2008).
   PubMed Web of Science ®Google Scholar
• Lehmann U, Hasemeier B, Christgen M et al. Epigenetic inactivation of microRNA gene hsa-mir-9–1 in human breast cancer. J. Pathol.214(1), 17–24 (2008).
   PubMed Web of Science ®Google Scholar